<DOC>
	<DOCNO>NCT02684006</DOCNO>
	<brief_summary>This phase 3 randomize trial evaluate anti-tumor activity safety avelumab combination axitinib sunitinib monotherapy , administer first-line treatment , patient advance renal cell carcinoma</brief_summary>
	<brief_title>A Study Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer ( JAVELIN Renal 101 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically cytologically confirm advanced metastatic RCC clear cell component Availability formalinfixed , paraffinembedded ( FFPE ) tumor tissue block de novo tumor biopsy screening ( biopsied tumor lesion RECIST target lesion ) . Alternatively , recently obtain archival FFPE tumor tissue block ( cut slide ) primary metastatic tumor resection biopsy provide follow criterion meet : 1 ) biopsy resection perform within 1 year randomization AND 2 ) patient receive intervening systemic anticancer treatment time tissue obtain randomization onto current study . If FFPE tissue block provide per documented regulation , 15 unstained slide ( 10 minimum ) acceptable Availability archival FFPE tumor tissue primary tumor resection specimen ( provide per ) . If FFPE tissue block providedas per document regulation 15 unstained slide ( 10 minimum ) acceptable At least one measureable lesion define RECIST version 1.1 previously irradiate . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bone marrow function , renal liver function Prior systemic therapy direct advanced metastatic RCC . Prior adjuvant neoadjuvant therapy RCC disease progression relapse occur within 12 month last dose treatment Prior immunotherapy IL2 , IFNα , anti PD 1 , anti PD L1 , anti PD L2 , anti CD137 , anti cytotoxic T lymphocyte associate antigen 4 ( CTLA 4 ) antibody ( include ipilimumab ) , antibody drug specifically target T cell co stimulation immune checkpoint pathway Prior therapy axitinib and/or sunitinib well prior therapy VEGF pathway inhibitor . Known severe hypersensitivity reaction monoclonal antibody ( Grade ≥3 ) , history anaphylaxis , uncontrolled asthma ( ie , 3 feature partially control asthma Global Initiative Asthma 2011 ) . Any follow previous 12 month : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , LVEF less LLN , clinically significant pericardial effusion , cerebrovascular accident , transient ischemic attack . Any following previous 6 month : deep vein thrombosis symptomatic pulmonary embolism . Vaccination within 4 week first dose avelumab trial prohibit except administration inactivate vaccine ( example , inactivate influenza vaccine ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>renal cell cancer</keyword>
	<keyword>kidney disease</keyword>
	<keyword>kidney neoplasm</keyword>
	<keyword>axitinib , sunitinib</keyword>
</DOC>